skip to Main Content
our leadership
Dedicating endless research and development for innovative anticancer drugs,
treatment of CNS and infectious diseases for the ultimate well-being of mankind.
Perpetual Pharmaceutical Pearl Provider,
ABION

“ At Abion, our objective is to develop first-ever
companion diagnostics-based drugs in Korea.”

With cutting-edge resources at our disposal, treatments will be personalized and
developed based on our patients’ individual biomarkers.

Research & Development
Through our national research projects, we are developing the anticancer inhibiting agent ABN401, a biobetter for treatment of multiple sclerosis, and medical countermeasures for Acute Radiation Syndrome (ARS) and infectious diseases, a lineup that we are promoting through globally certified clinical processes towards eventual commercialization across international markets.
abion
Anticancer Therapies
abion
Treatment for Multiple Sclerosis
abion
Medical Countermeasures (MCM)

NEWS + more

Announcement of 7th General Shareholders’ Meeting

Date of Post: March 27, 2015 We held a workshop to kick off a fresh…

2014 Annual Reference Biolab Workshop

Date of Post: March 27, 2015 We have held a workshop to kick off a…

NOTICE + more

Announcement of 8th Extraordinary General Shareholders’ Meeting

Date of Post: March 27, 2015 In accordance with provisions of Article 22 in our…

Abion KONEX Certificate of Merit & Proclamation of CI Award

Date of Post: March 27, 2015 On July 22, 2014, the Best Western Premier Hotel…

CONTACT US

Back To Top